Dermot Mark Increases Stake in Cencora, Inc.
Insider Dermot Mark purchased 4,000 shares of Cencora, Inc., reflecting ongoing interest in the company's stock.
Key Points
- Insider Dermot Mark purchased 4,000 shares of Cencora, Inc. at $274.19 each on June 18, 2026, totaling about $1.1 million.
- Cencora, Inc. trades around $271.83, with a market cap of $52.9 billion and a P/E ratio of 20.83.
- Barclays, Wells Fargo, and UBS maintain 'buy' ratings for Cencora, with price targets ranging from $331 to $412.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, insider Dermot Mark bought 4,000 shares of Cencora, Inc. (NYSE:COR) at an average price of $274.19 per share. This transaction was valued at approximately $1.1 million. The purchase was not part of a pre-planned trading program, indicating a direct investment move by Mark.
Insider Buying and Selling at Cencora, Inc.
Dermot Mark's recent purchase follows another buy of 4,000 shares on May 28, 2026, at $266.26 each. Other insiders, including Dennis Nally, Ellen Cooper, and Lauren Tyler, also acquired shares in early May at $304 each. In April, Lazarus Krikorian, the SVP & Chief Accounting Officer, bought 3,936 shares.
Other Institutional Activity in Cencora
Institutional investors have been active in Cencora as well. BlackRock, Inc. reduced its holdings by 342,442 shares, leaving it with 19,943,637 shares valued at about $6.27 billion, a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 12,313,459 shares worth approximately $3.87 billion. Similarly, Vanguard Portfolio Management LLC also initiated a stake with 9,590,414 shares valued at $3.01 billion. State Street Corp decreased its holdings by 114,956 shares, now holding 9,190,551 shares worth about $2.89 billion, a 1.2% reduction. Meanwhile, Price T Rowe Associates Inc added 330,881 shares, increasing its position by 4.7% to 7,323,706 shares valued at $2.3 billion.
Cencora, Inc. Stock Down 15.6%
Shares of NYSE:COR traded near $271.83 on Tuesday. Cencora, Inc. has a market cap of approximately $52.9 billion and a P/E ratio of 20.83. The stock's 52-week range is between $244.82 and $377.54, with a 50-day moving average of $285.78 and a 200-day moving average of $324.84. The company has a beta of 0.588, indicating lower volatility compared to the market.
$COR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Cencora reported revenue of $328.68 billion with a growth of 3.8%. The company achieved an EPS of $13.05, a net margin of 0.775%, and a return on equity of 1.07%. The next earnings report is expected on August 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 2.3%. Revenue missed estimates by 4.3%.
-
Profit surprise
EBITDA beat by 9 percent. Operating income met by 2 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 0.8 points. Positive free cash flow.
Earnings Call Summary
The company delivered a strong first quarter with 12 percent operating income growth and 9 percent earnings per share growth, driven by continued strength in specialty pharmaceuticals, particularly GLP-1 products which grew 11 percent. Management highlighted that US healthcare solutions performed at the high end of long-term guidance even excluding recent acquisitions like RCA and the newly closed OneOncology deal. The completion of the OneOncology acquisition marks a major strategic expansion of Cencora's managed service organization platform, which management views as a natural extension of its specialty pharmaceutical leadership.
Guidance Cencora raised full year revenue growth guidance to 7 to 9 percent from 5 to 7 percent, and operating income growth to 11.5 to 13.5 percent from 8 to 10 percent. The company closed its OneOncology acquisition and expects the MSO platform to drive meaningful operating income expansion this year and beyond.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Cencora offers an annual dividend rate of $2.40, yielding 0.88% with a payout ratio of 17.62%.
Analysts Set New Price Targets
Barclays maintained a 'buy' rating on June 10, 2026, with a price target of $350. Wells Fargo and UBS also maintained 'buy' ratings with targets of $331 and $412, respectively. The consensus recommendation is a 'buy', with an average target price of $350.58 from 12 analysts.
About Cencora, Inc.
Cencora, Inc., based in Conshohocken, Pennsylvania, is a key player in the healthcare sector, specializing in medical distribution. The company provides pharmaceutical products and related services both in the United States and internationally. Led by CEO Dr. Robert P. Mauch, Cencora employs around 47,000 people. Formerly known as AmerisourceBergen Corporation, it rebranded to Cencora in August 2023.
Bottom Line
Dermot Mark's purchase of Cencora shares underscores ongoing insider interest in the company. This activity is part of a broader pattern of institutional investments and analyst positivity, with several firms maintaining 'buy' ratings. As always, it's important to remember that insider transactions are disclosed after they occur and may not reflect the current position.
Get Cencora, Inc. alerts
New 13F filings, insider trades, and analyst moves on $COR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.